Valor202020212022202320242025TTMDespesas comerciais, gerais e administrativas1.25 B1.2 B1.36 B1.47 B1.54 B1.67 B1.72 BPesquisa e desenvolvimento———————Lucro operacional1.69 B1.8 B1.34 B1.6 B2.09 B2.04 B2.09 BLucro não operacional, total16.76 M6.38 M-15.77 M-19.18 M-69.81 M-102.69 M-80.67 MDespesa com juros, líquida de juros capitalizados300.88 M282.32 M351.92 M383.13 M443.18 M539.92 M—Receitas não operacionais, líquidas das despesas com juros-300.88 M-282.32 M-351.92 M-383.13 M-443.18 M-539.92 M0Receitas/despesas incomuns16.76 M6.38 M-15.77 M-19.18 M-69.81 M-102.69 M-80.67 MLucro antes dos impostos1.32 B1.52 B966.28 M1.18 B1.53 B1.35 B1.4 BParticipação no lucro26.92 M26.94 M26.52 M27.86 M26.19 M33 M35.73 MImpostos313.93 M306.73 M198.09 M220.12 M279.66 M293.11 M305.19 MParticipação de minoritários221.03 M233.31 M221.24 M265.44 M314.39 M331.91 M340.12 MOutras receitas/despesas após impostos-747 K-11.23 M-21.69 M8.94 M-13.41 M17.55 M17.98 MLucro líquido antes das operações descontinuadas783.29 M978.45 M546.95 M691.53 M936.34 M721.8 M781.42 MOperações descontinuadas-9.65 M013.45 M0025 M—Lucro líquido773.64 M978.45 M560.4 M691.53 M936.34 M746.8 M781.42 MAjuste de diluição———————Dividendos de ações preferenciais———————Lucro líquido diluído disponível aos acionistas773.64 M978.45 M560.4 M691.53 M936.34 M746.8 M781.42 MLucro básico por ação6.469.36.037.6211.0210.0610.94Lucro diluído por ação6.318.95.857.4210.739.8410.71Número médio de ações básicas119.8 M105.23 M92.99 M90.79 M84.99 M74.23 M—Ações diluídas122.62 M109.95 M95.83 M93.18 M87.27 M75.89 M—EBITDA2.31 B2.47 B2.06 B2.34 B2.81 B2.75 B—EBIT1.69 B1.8 B1.34 B1.6 B2.09 B2.04 B2.09 BCusto da receita———————Outros componentes do custo———————Amortização e depreciação (fluxo de caixa)616.63 M667.75 M721.13 M736.47 M716.4 M708.25 M—
DaVita Inc. Common Stock
DaVita Inc., incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients, and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease, which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
In 2025, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2025, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2025, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.
The company is ranked 331st on the Fortune 500.